Advertisement

Sildenafil citrate (viagra) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects

      Abstract

      Objectives. To evaluate the efficacy, safety, and tolerability of sildenafil in men with broad-spectrum erectile dysfunction (ED), with reference to age-matched healthy control subjects.
      Methods. One hundred eleven patients were enrolled in a randomized, double-blind, placebo-controlled, parallel-group, 12-week, flexible-dose study. Efficacy assessments included the International Index of Erectile Function (IIEF), a global assessment question, and patient event log data. In a separate, nontreatment study, 109 control subjects also completed the IIEF.
      Results. Mean IIEF scores at baseline were significantly lower for patients with ED than for control subjects without a history of ED. After treatment, mean IIEF scores for patients receiving sildenafil approached values observed in control subjects and were significantly higher than mean scores for patients receiving placebo (P <0.01). Responses to the global assessment question and patient log data corroborated the IIEF results. Sildenafil was well tolerated, with no discontinuations because of adverse events.
      Conclusions. The results indicate that sildenafil, an effective oral therapy for the treatment of broad-spectrum ED, is associated with a near normalization of patient erectile function.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • NIH Consensus Development Panel on Impotence
        Impotence.
        JAMA. 1993; 270: 83-90
        • Feldman H
        • Goldstein I
        • Hatzichristou D.G
        • et al.
        Impotence and its medical and psychosocial correlates.
        J Urol. 1994; 151: 54-61
        • Lerner S.E
        • Melman A
        • Christ G.J
        A review of erectile dysfunction.
        J Urol. 1993; 149: 1246-1255
        • Krane R.J
        • Goldstein I
        • Saenz de Tejada I
        Impotence.
        N Engl J Med. 1989; 321: 1648-1659
        • Montague D.K
        • Barada J.H
        • Belker A.M
        • et al.
        Clinical guidelines panel on erectile dysfunction.
        J Urol. 1996; 156: 2007-2011
        • Benet A.E
        • Sharaby J.S
        • Melman A
        Male erectile dysfunction assessment and treatment options.
        Compr Ther. 1994; 20: 669-673
        • Conte H.R
        Development and use of self-report techniques for assessing sexual function.
        Arch Sex Behav. 1983; 12: 555-576
        • Anderson B.L
        • Boffit B
        Is there a reliable and valid self-report measure of sexual function?.
        Arch Sex Behav. 1988; 17: 509-525
        • Rosen R.C
        • Riley A
        • Wagner G
        • et al.
        The International Index of Erectile Function (IIEF).
        Urology. 1997; 49: 822-830
        • Andersson K.-E
        • Wagner G
        Physiology of penile erection.
        Physiol Rev. 1995; 75: 191-236
        • Bush P.A
        • Aronson W.J
        • Buga G.M
        • et al.
        Nitric oxide is a potent relaxant of human and rabbit corpus cavernosum.
        J Urol. 1996; 147: 1650-1655
        • Ignarro L.J
        • Bush P.A
        • Buga G.M
        • et al.
        Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle.
        Biochem Biophys Res Commun. 1990; 170: 843-850
        • Burnett A.L
        Nitric oxide in the penis.
        J Urol. 1997; 157: 320-324
        • Boolell M
        • Allen M.J
        • Ballard S.A
        • et al.
        Sildenafil.
        Int J Impot Res. 1996; 8: 47-52
        • Boolell M
        • Gepi-Attee S
        • Gingell J.C
        • et al.
        Sildenafil, a novel effective oral therapy for male erectile dysfunction.
        Br J Urol. 1996; 78: 257-261
        • Goldstein I
        • Lue T.F
        • Padma-Nathan H
        • et al.
        Oral sildenafil in the treatment of erectile dysfunction.
        N Engl J Med. 1998; 338: 1397-1404
        • Levine S.B
        • Althof S.E
        • Turner L.A
        • et al.
        Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence.
        J Urol. 1989; 141: 54-57
        • Lakin M.M
        • Montague D.K
        • VanderBrug Mendendorp S
        • et al.
        Intracavernous injection therapy.
        J Urol. 1990; 143: 1138-1141
        • Hollander J.B
        • Gonzalez J
        • Norman T
        Patient satisfaction with pharmacologic erection program.
        Urology. 1992; 39: 439-441
        • Sundaram C.P
        • Thomas W
        • Pryor L.E
        • et al.
        Long-term follow-up of patients receiving injection therapy for erectile dysfunction.
        Urology. 1997; 49: 932-935